PPIG and infection: Levonadifloxacin, a novel broad-spectrum fluoroquinolone, effectively targets challenging infections caused by multidrug-resistant Gram-positive, intracellular, atypical, anaerobic, and Gram-negative bacteria, particularly respiratory pathogens, with superior safety, tolerability, and minimal drug-drug interactions attributed to its lack of CYP interaction [68].